Kallikrein 5/KLK5, His, Human
Kallikrein 5/KLK5, His, Human

Immobilized Kallikrein 5/KLK5, His, Human, His Tag at 0.5 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-Kallikrein 5 Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.

Kallikrein 5/KLK5, His, Human

The purity of Kallikrein 5/KLK5, His, Human is greater than 95% as determined by SEC-HPLC.

Kallikrein 5/KLK5, His, Human

Kallikrein 5/KLK5, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Kallikrein 5/KLK5, His, Human

The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
Z05543
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Kallikrein 5/KLK5 (Val23-Ser293)_x000D_
Accession # Q9Y337		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. Measured by its ability to cleave the fluorogenic peptide substrate Boc­VPR­AMC. Test result was comparable to standard batch
Expression System HEK293
Theoretical Molecular Weight 30.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 42-48 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl (pH 5.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCl (pH 5.5).
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Kallikrein 5/KLK5, His, Human
    • Kallikrein 5/KLK5, His, Human

    Immobilized Kallikrein 5/KLK5, His, Human, His Tag at 0.5 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-Kallikrein 5 Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.

  • Kallikrein 5/KLK5, His, Human
    • Kallikrein 5/KLK5, His, Human

    The purity of Kallikrein 5/KLK5, His, Human is greater than 95% as determined by SEC-HPLC.

  • Kallikrein 5/KLK5, His, Human
    • Kallikrein 5/KLK5, His, Human

    Kallikrein 5/KLK5, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
Synonyms Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.